POST Online Media Lite Edition



 

Roche acquires IQuum for $275 million

Staff writer |
Roche announced the acquisition of IQuum, Inc. based in Marlborough, Massachusetts, USA. IQuum is a privately held company focused on developing point of care offerings for the molecular diagnostics market.

Article continues below






Under the terms of the agreement, Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product related milestones. The transaction is subject to customary closing conditions.

The acquisition will provide Roche with access to IQuum’s Laboratory-in-a-tube (Liat) System, which enables healthcare workers to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training. The Liat™ Analyzer and Liat Influenza A/B Assay, the first test available for use on the system, produce reliable and accurate lab-like results and are CE marked and FDA cleared.

"With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment. Patients will benefit from on-the-spot and accurate diagnoses, which will allow healthcare professionals to make rapid, informed treatment decisions in flexible settings,” said Roland Diggelmann, COO of Roche Diagnostics.

"We are very excited to continue developing innovative molecular diagnostics solutions as part of the Roche Molecular Diagnostics team,” said Shuqi Chen, Ph.D., CEO and founder of IQuum.

Once the transaction is complete, IQuum will be integrated into Roche Molecular Diagnostics.


What to read next

Roche acquires Genia Technologies
Roche buys superbug diagnostics firm for up to $425 million
Roche to acquire Santaris Pharma